The Trump administration’s move to end Medicare’s Part D Premium Stabilization Demonstration cuts off a temporary subsidy that had been keeping seniors’ drug plan premiums from jumping after recent changes to Medicare’s drug benefit. The Stabilization Demonstration will end on Jan. 1, 2027.
The program, launched in 2024 was designed to ease the shift to the Inflation Reduction Act’s new cost-sharing rules, enabling insurers to hold premiums down and avoid the steep increases federal auditors warned were coming. Ending it before the 2027 plan year removes about $10 billion in support, leaving insurers to absorb higher costs and likely to pass them on to seniors.
What does this mean to seniors? Experts say stand-alone Part D premiums may rise, and plan choices may become more volatile.
For older Americans living on fixed incomes, even a premium increase that sounds modest can mean choosing between a prescription plan, groceries, utilities, or other necessities.
Clarification Needed
There’s been a lot of confusion about Trump’s ending Medicare’s Part D Premium Stabilization Demonstration. The public should know clearly what will and will not happen.
WILL DO. What the Trump Medicare subsidy discontinuation will do based on reporting from MedPage Today and U.S. News includes: 1) Increase Medicare Part D premiums in 2027. Millions of older adults will face higher monthly drug plan costs once the temporary subsidies end. 2) Remove federal financial support that kept premiums lower. The Biden administration created these subsidies to stabilize premiums after the Inflation Reduction Act changed insurer cost structures. Ending them removes that cushion. 3) Shift more costs onto seniors and insurers. Insurers will again bear more of the drug-cost burden, which typically leads to higher premiums for beneficiaries. 4) Reduce federal spending by eliminating $9.8 billion in subsidies. 5) Potentially raise costs for 23–25 million Medicare Part D enrollees
WILL NOT DO. What the discontinuation will NOT do: 1) First and most important, contrary to rumors, it will not end Medicare Part D drug coverage. The program continues; only the temporary premium-stabilizing subsidies are ending. 2) It will not eliminate the Inflation Reduction Act’s $2,000 out-of-pocket cap. The cap remains in place for 2025 and beyond. 3) It will not raise pharmacy counter costs directly. Premiums may rise, but point-of-sale drug costs remain capped. 4) It will not change Medicare eligibility or enrollment rules. 5) It will not affect Medicare Parts A or B. The change is limited to Part D prescription drug plans.
In sum, it is not the disappearance of prescription drug coverage, but it is the removal of a tool that helped prevent premiums from jumping during a major policy transition. It is not fiscally meaningless, but neither is it cost-free for seniors.
Solutions
In the short term instead of abruptly ending Medicare’s Part D Premium Stabilization Demonstration, it should have been phased out gradually. A multi-year phase out would have given seniors time to switch plans or prepare for higher costs. There should also be an automatic plan-switching protections systems that would auto-reassign beneficiaries to lower-cost plans if costs rise sharply.
Medicare’s Part D Premium Stabilization Demonstration was designed to be temporary. Possible long-term solutions experts say should have been done instead are 1) to increase federal reinsurance slightly, 2) modify the catastrophic coverage formula, and 3) smooth the liability curve for plans. This reduces pressure on premiums without direct subsidies.
Remember the original intent of Medicare
The original intent of Medicare was to make healthcare affordable for seniors who are no longer strong enough to work. Part D promised better protection from crushing prescription expenses. Letting premiums climb unchecked risks weakening that original promise that the programed was designed for.
A Medicare-for-All solution
A majority of Americans support Medicare-for-All and it’s time that politicians give it a serious look. A Medicare-for-All approach to Part D would replace today’s fragmented drug-plan system with a single, national prescription benefit that covers everyone automatically, with no premiums, no plan shopping, and no private bidding. Instead of subsidizing insurers to keep premiums down, the government would negotiate drug prices directly, set one unified formulary, and use its purchasing power to lower costs for all patients.
This model would eliminate the need for temporary stabilization programs entirely because drug coverage would be financed through the broader Medicare-for-All system, spreading risk across the whole population and ensuring predictable, affordable access to medications for every American.
The powerful Big Pharma and health insurance lobbies are doing all they can to keep the status quo but as the cost of almost everything rise to unaffordable prices, politicians should be reminded that a majority of Americans believe healthcare is a right, not a luxury.
Most Americans will not understand the complexities of temporary subsidies for drug prices, why they’re needed or how ending them will raise their premiums. Americans want affordability especially when it comes to healthcare. Let this message sink in for politicians.
+ There are no comments
Add yours